Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures.

Schroeder MP, Bastian L, Eckert C, Gökbuget N, James AR, Tanchez JO, Schlee C, Isaakidis K, Häupl B, Baum K, Migueles Lozano OA, Kouidri K, Pan KT, Urlaub H, Schwartz S, Burmeister T, von Stackelberg A, Hoelzer D, Pfeiffer H, Rieger MA, Göllner S, Oellerich T, Horstman M, Schrappe M, Wolf J, Kirschner-Schwabe R, Brüggemann M, Müller-Tidow C, Serve H, Neumann M, Baldus CD.

Sci Rep. 2019 Mar 12;9(1):4188. doi: 10.1038/s41598-019-40786-1.

2.

PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia.

Bastian L, Schroeder MP, Eckert C, Schlee C, Tanchez JO, Kämpf S, Wagner DL, Schulze V, Isaakidis K, Lázaro-Navarro J, Hänzelmann S, James AR, Ekici A, Burmeister T, Schwartz S, Schrappe M, Horstmann M, Vosberg S, Krebs S, Blum H, Hecht J, Greif PA, Rieger MA, Brüggemann M, Gökbuget N, Neumann M, Baldus CD.

Leukemia. 2019 Mar 6. doi: 10.1038/s41375-019-0430-z. [Epub ahead of print]

PMID:
30842609
3.

Aneuploidy in children with relapsed B-cell precursor acute lymphoblastic leukaemia: clinical importance of detecting a hypodiploid origin of relapse.

Groeneveld-Krentz S, Schroeder MP, Reiter M, Pogodzinski MJ, Pimentel-Gutiérrez HJ, Vagkopoulou R, Hof J, Chen-Santel C, Nebral K, Bradtke J, Türkmen S, Baldus CD, Gattenlöhner S, Haas OA, von Stackelberg A, Karawajew L, Eckert C, Kirschner-Schwabe R.

Br J Haematol. 2019 Apr;185(2):266-283. doi: 10.1111/bjh.15770. Epub 2019 Feb 3.

PMID:
30714092
4.

Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia.

James AR, Schroeder MP, Neumann M, Bastian L, Eckert C, Gökbuget N, Tanchez JO, Schlee C, Isaakidis K, Schwartz S, Burmeister T, von Stackelberg A, Rieger MA, Göllner S, Horstman M, Schrappe M, Kirschner-Schwabe R, Brüggemann M, Müller-Tidow C, Serve H, Akalin A, Baldus CD.

J Hematol Oncol. 2019 Jan 14;12(1):8. doi: 10.1186/s13045-018-0692-3.

5.

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.

Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlägel U, Mütherig A, Fransecky L, Noppeney R, Bug G, Götze KS, Krämer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stölzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hänel M, Dührsen U, Schetelig J, Röllig C, Kramer M, Ehninger G, Bornhäuser M, Thiede C.

Lancet Oncol. 2018 Dec;19(12):1668-1679. doi: 10.1016/S1470-2045(18)30580-1. Epub 2018 Nov 12.

PMID:
30442503
6.

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M.

Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.

PMID:
29859851
7.

Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients.

Greif PA, Hartmann L, Vosberg S, Stief SM, Mattes R, Hellmann I, Metzeler KH, Herold T, Bamopoulos SA, Kerbs P, Jurinovic V, Schumacher D, Pastore F, Bräundl K, Zellmeier E, Ksienzyk B, Konstandin NP, Schneider S, Graf A, Krebs S, Blum H, Neumann M, Baldus CD, Bohlander SK, Wolf S, Görlich D, Berdel WE, Wörmann BJ, Hiddemann W, Spiekermann K.

Clin Cancer Res. 2018 Apr 1;24(7):1716-1726. doi: 10.1158/1078-0432.CCR-17-2344. Epub 2018 Jan 12.

8.

Targeting the leukemic bone marrow microenvironment.

von der Heide EK, Neumann M, Baldus CD.

Oncotarget. 2017 Oct 27;8(57):96474-96475. doi: 10.18632/oncotarget.22103. eCollection 2017 Nov 14. No abstract available.

9.

Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations.

Heidrich K, Thiede C, Schäfer-Eckart K, Schmitz N, Aulitzky WE, Krämer A, Rösler W, Hänel M, Einsele H, Baldus CD, Trappe RU, Stölzel F, Middeke JM, Röllig C, Taube F, Kramer M, Serve H, Berdel WE, Ehninger G, Bornhäuser M, Schetelig J; Study Alliance Leukemia (SAL).

Ann Oncol. 2017 Nov 1;28(11):2793-2798. doi: 10.1093/annonc/mdx500.

PMID:
28945881
10.

Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.

Silva P, Neumann M, Schroeder MP, Vosberg S, Schlee C, Isaakidis K, Ortiz-Tanchez J, Fransecky LR, Hartung T, Türkmen S, Graf A, Krebs S, Blum H, Müller-Tidow C, Thiede C, Ehninger G, Serve H, Hecht J, Berdel WE, Greif PA, Röllig C, Baldus CD.

Leukemia. 2017 Jul;31(7):1640-1644. doi: 10.1038/leu.2017.109. Epub 2017 Apr 3. No abstract available.

PMID:
28366934
11.

Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients.

von der Heide EK, Neumann M, Vosberg S, James AR, Schroeder MP, Ortiz-Tanchez J, Isaakidis K, Schlee C, Luther M, Jöhrens K, Anagnostopoulos I, Mochmann LH, Nowak D, Hofmann WK, Greif PA, Baldus CD.

Leukemia. 2017 May;31(5):1069-1078. doi: 10.1038/leu.2016.324. Epub 2016 Nov 11.

PMID:
27833093
12.

Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.

Mansouri L, Noerenberg D, Young E, Mylonas E, Abdulla M, Frick M, Asmar F, Ljungström V, Schneider M, Yoshida K, Skaftason A, Pandzic T, Gonzalez B, Tasidou A, Waldhueter N, Rivas-Delgado A, Angelopoulou M, Ziepert M, Arends CM, Couronné L, Lenze D, Baldus CD, Bastard C, Okosun J, Fitzgibbon J, Dörken B, Drexler HG, Roos-Weil D, Schmitt CA, Munch-Petersen HD, Zenz T, Hansmann ML, Strefford JC, Enblad G, Bernard OA, Ralfkiaer E, Erlanson M, Korkolopoulou P, Hultdin M, Papadaki T, Grønbæk K, Lopez-Guillermo A, Ogawa S, Küppers R, Stamatopoulos K, Stavroyianni N, Kanellis G, Rosenwald A, Campo E, Amini RM, Ott G, Vassilakopoulos TP, Hummel M, Rosenquist R, Damm F.

Blood. 2016 Dec 8;128(23):2666-2670. Epub 2016 Sep 26.

13.

Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL.

Fransecky L, Neumann M, Heesch S, Schlee C, Ortiz-Tanchez J, Heller S, Mossner M, Schwartz S, Mochmann LH, Isaakidis K, Bastian L, Kees UR, Herold T, Spiekermann K, Gökbuget N, Baldus CD.

J Hematol Oncol. 2016 Sep 22;9(1):95.

14.

Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis.

Herold T, Schneider S, Metzeler KH, Neumann M, Hartmann L, Roberts KG, Konstandin NP, Greif PA, Bräundl K, Ksienzyk B, Huk N, Schneider I, Zellmeier E, Jurinovic V, Mansmann U, Hiddemann W, Mullighan CG, Bohlander SK, Spiekermann K, Hoelzer D, Brüggemann M, Baldus CD, Dreyling M, Gökbuget N.

Haematologica. 2017 Jan;102(1):130-138. doi: 10.3324/haematol.2015.136366. Epub 2016 Aug 25.

15.

A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma.

Joosten M, Ginzel S, Blex C, Schmidt D, Gombert M, Chen C, Linka RM, Gräbner O, Hain A, Hirsch B, Sommerfeld A, Seegebarth A, Gruber U, Maneck C, Zhang L, Stenin K, Dieks H, Sefkow M, Münk C, Baldus CD, Thiele R, Borkhardt A, Hummel M, Köster H, Fischer U, Dreger M, Seitz V.

Mol Oncol. 2016 Oct;10(8):1232-44. doi: 10.1016/j.molonc.2016.06.001. Epub 2016 Jun 9.

16.

Close correlation of copy number aberrations detected by next-generation sequencing with results from routine cytogenetics in acute myeloid leukemia.

Vosberg S, Herold T, Hartmann L, Neumann M, Opatz S, Metzeler KH, Schneider S, Graf A, Krebs S, Blum H, Baldus CD, Hiddemann W, Spiekermann K, Bohlander SK, Mansmann U, Greif PA.

Genes Chromosomes Cancer. 2016 Jul;55(7):553-67. doi: 10.1002/gcc.22359. Epub 2016 May 2.

PMID:
27015608
17.

Karyotype complexity and prognosis in acute myeloid leukemia.

Stölzel F, Mohr B, Kramer M, Oelschlägel U, Bochtler T, Berdel WE, Kaufmann M, Baldus CD, Schäfer-Eckart K, Stuhlmann R, Einsele H, Krause SW, Serve H, Hänel M, Herbst R, Neubauer A, Sohlbach K, Mayer J, Middeke JM, Platzbecker U, Schaich M, Krämer A, Röllig C, Schetelig J, Bornhäuser M, Ehninger G.

Blood Cancer J. 2016 Jan 15;6:e386. doi: 10.1038/bcj.2015.114.

18.

TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.

Middeke JM, Herold S, Rücker-Braun E, Berdel WE, Stelljes M, Kaufmann M, Schäfer-Eckart K, Baldus CD, Stuhlmann R, Ho AD, Einsele H, Rösler W, Serve H, Hänel M, Sohlbach K, Klesse C, Mohr B, Heidenreich F, Stölzel F, Röllig C, Platzbecker U, Ehninger G, Bornhäuser M, Thiede C, Schetelig J; Study Alliance Leukaemia (SAL).

Br J Haematol. 2016 Mar;172(6):914-22. doi: 10.1111/bjh.13912. Epub 2016 Jan 13.

PMID:
26771088
19.

Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.

Ho AD, Schetelig J, Bochtler T, Schaich M, Schäfer-Eckart K, Hänel M, Rösler W, Einsele H, Kaufmann M, Serve H, Berdel WE, Stelljes M, Mayer J, Reichle A, Baldus CD, Schmitz N, Kramer M, Röllig C, Bornhäuser M, Thiede C, Ehninger G; Study Alliance Leukemia.

Biol Blood Marrow Transplant. 2016 Mar;22(3):462-9. doi: 10.1016/j.bbmt.2015.10.023. Epub 2015 Nov 10.

20.

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia.

Lancet Oncol. 2015 Dec;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9. Epub 2015 Nov 6.

PMID:
26549589
21.

Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.

Müller-Tidow C, Tschanter P, Röllig C, Thiede C, Koschmieder A, Stelljes M, Koschmieder S, Dugas M, Gerss J, Butterfaß-Bahloul T, Wagner R, Eveslage M, Thiem U, Krause SW, Kaiser U, Kunzmann V, Steffen B, Noppeney R, Herr W, Baldus CD, Schmitz N, Götze K, Reichle A, Kaufmann M, Neubauer A, Schäfer-Eckart K, Hänel M, Peceny R, Frickhofen N, Kiehl M, Giagounidis A, Görner M, Repp R, Link H, Kiani A, Naumann R, Brümmendorf TH, Serve H, Ehninger G, Berdel WE, Krug U; Study Alliance Leukemia Group.

Leukemia. 2016 Mar;30(3):555-61. doi: 10.1038/leu.2015.306. Epub 2015 Nov 2.

PMID:
26522083
22.

Inhibition of IGF1-R overcomes IGFBP7-induced chemotherapy resistance in T-ALL.

Bartram I, Erben U, Ortiz-Tanchez J, Blunert K, Schlee C, Neumann M, Heesch S, Baldus CD.

BMC Cancer. 2015 Oct 8;15:663. doi: 10.1186/s12885-015-1677-z.

23.

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.

Ostendorf BN, Nogai H, Baldus CD, Burmeister T, Arnold R.

Biomark Insights. 2015 Aug 30;10(Suppl 3):25-8. doi: 10.4137/BMI.S22279. eCollection 2015.

24.

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.

Fransecky L, Mochmann LH, Baldus CD.

Mol Cell Ther. 2015 Mar 20;3:2. doi: 10.1186/s40591-015-0040-8. eCollection 2015.

25.

Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.

Kühnl A, Valk PJ, Sanders MA, Ivey A, Hills RK, Mills KI, Gale RE, Kaiser MF, Dillon R, Joannides M, Gilkes A, Haferlach T, Schnittger S, Duprez E, Linch DC, Delwel R, Löwenberg B, Baldus CD, Solomon E, Burnett AK, Grimwade D.

Blood. 2015 May 7;125(19):2985-94. doi: 10.1182/blood-2014-12-613703. Epub 2015 Mar 24.

26.

Mutational spectrum of adult T-ALL.

Neumann M, Vosberg S, Schlee C, Heesch S, Schwartz S, Gökbuget N, Hoelzer D, Graf A, Krebs S, Bartram I, Blum H, Brüggemann M, Hecht J, Bohlander SK, Greif PA, Baldus CD.

Oncotarget. 2015 Feb 20;6(5):2754-66.

27.

Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.

Röllig C, Bornhäuser M, Kramer M, Thiede C, Ho AD, Krämer A, Schäfer-Eckart K, Wandt H, Hänel M, Einsele H, Aulitzky WE, Schmitz N, Berdel WE, Stelljes M, Müller-Tidow C, Krug U, Platzbecker U, Wermke M, Baldus CD, Krause SW, Stölzel F, von Bonin M, Schaich M, Serve H, Schetelig J, Ehninger G.

J Clin Oncol. 2015 Feb 10;33(5):403-10. doi: 10.1200/JCO.2013.54.4973. Epub 2014 Dec 29. Erratum in: J Clin Oncol. 2015 May 1;33(13):1519.

PMID:
25547501
28.

Ph-like acute lymphoblastic leukemia in older adults.

Herold T, Baldus CD, Gökbuget N.

N Engl J Med. 2014 Dec 4;371(23):2235. doi: 10.1056/NEJMc1412123#SA1. No abstract available.

PMID:
25470705
29.

Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.

Schetelig J, Schaich M, Schäfer-Eckart K, Hänel M, Aulitzky WE, Einsele H, Schmitz N, Rösler W, Stelljes M, Baldus CD, Ho AD, Neubauer A, Serve H, Mayer J, Berdel WE, Mohr B, Oelschlägel U, Parmentier S, Röllig C, Kramer M, Platzbecker U, Illmer T, Thiede C, Bornhäuser M, Ehninger G; Study Alliance Leukemia.

Leukemia. 2015 May;29(5):1060-8. doi: 10.1038/leu.2014.335. Epub 2014 Dec 1.

PMID:
25434303
30.

Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients.

Bartram I, Gökbuget N, Schlee C, Heesch S, Fransecky L, Schwartz S, Stuhlmann R, Schäfer-Eckhart K, Starck M, Reichle A, Hoelzer D, Baldus CD, Neumann M.

J Hematol Oncol. 2014 Jul 15;7:51. doi: 10.1186/s13045-014-0051-y.

31.

FAT1 expression and mutations in adult acute lymphoblastic leukemia.

Neumann M, Seehawer M, Schlee C, Vosberg S, Heesch S, von der Heide EK, Graf A, Krebs S, Blum H, Gökbuget N, Schwartz S, Hoelzer D, Greif PA, Baldus CD.

Blood Cancer J. 2014 Jun 27;4:e224. doi: 10.1038/bcj.2014.44. No abstract available.

32.

R-split-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma.

Kreher S, Lammer F, Augustin D, Pezzutto A, Baldus CD.

Eur J Haematol. 2014 Jul;93(1):70-6. doi: 10.1111/ejh.12304. Epub 2014 Mar 28.

PMID:
24612334
33.

ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells.

Mochmann LH, Neumann M, von der Heide EK, Nowak V, Kühl AA, Ortiz-Tanchez J, Bock J, Hofmann WK, Baldus CD.

Oncotarget. 2014 Jan 30;5(2):351-62.

34.

Mutational landscape of adult ETP-ALL.

Neumann M, Greif PA, Baldus CD.

Oncotarget. 2013 Jul;4(7):954-5. No abstract available.

35.

High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.

Schaich M, Parmentier S, Kramer M, Illmer T, Stölzel F, Röllig C, Thiede C, Hänel M, Schäfer-Eckart K, Aulitzky W, Einsele H, Ho AD, Serve H, Berdel WE, Mayer J, Schmitz N, Krause SW, Neubauer A, Baldus CD, Schetelig J, Bornhäuser M, Ehninger G.

J Clin Oncol. 2013 Jun 10;31(17):2094-102. doi: 10.1200/JCO.2012.46.4743. Epub 2013 Apr 29.

PMID:
23630210
36.

Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations.

Neumann M, Heesch S, Schlee C, Schwartz S, Gökbuget N, Hoelzer D, Konstandin NP, Ksienzyk B, Vosberg S, Graf A, Krebs S, Blum H, Raff T, Brüggemann M, Hofmann WK, Hecht J, Bohlander SK, Greif PA, Baldus CD.

Blood. 2013 Jun 6;121(23):4749-52. doi: 10.1182/blood-2012-11-465138. Epub 2013 Apr 19.

37.

MicroRNA profiling reveals aberrant microRNA expression in adult ETP-ALL and functional studies implicate a role for miR-222 in acute leukemia.

Coskun E, Neumann M, Schlee C, Liebertz F, Heesch S, Goekbuget N, Hoelzer D, Baldus CD.

Leuk Res. 2013 Jun;37(6):647-56. doi: 10.1016/j.leukres.2013.02.019. Epub 2013 Mar 20.

PMID:
23522449
38.

Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization.

Heesch S, Neumann M, Schwartz S, Bartram I, Schlee C, Burmeister T, Hänel M, Ganser A, Heuser M, Wendtner CM, Berdel WE, Gökbuget N, Hoelzer D, Hofmann WK, Thiel E, Baldus CD.

Ann Hematol. 2013 Jun;92(6):747-58. doi: 10.1007/s00277-013-1694-4. Epub 2013 Feb 15.

PMID:
23412561
39.

FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.

Neumann M, Coskun E, Fransecky L, Mochmann LH, Bartram I, Sartangi NF, Heesch S, Gökbuget N, Schwartz S, Brandts C, Schlee C, Haas R, Dührsen U, Griesshammer M, Döhner H, Ehninger G, Burmeister T, Blau O, Thiel E, Hoelzer D, Hofmann WK, Baldus CD.

PLoS One. 2013;8(1):e53190. doi: 10.1371/journal.pone.0053190. Epub 2013 Jan 24.

40.

Skewed X-inactivation patterns in ageing healthy and myelodysplastic haematopoiesis determined by a pyrosequencing based transcriptional clonality assay.

Mossner M, Nolte F, Hütter G, Reins J, Klaumünzer M, Nowak V, Obländer J, Ackermann K, Will S, Röhl H, Neumann U, Neumann M, Hopfer O, Baldus CD, Hofmann WK, Nowak D.

J Med Genet. 2013 Feb;50(2):108-17. doi: 10.1136/jmedgenet-2012-101093.

PMID:
23339109
41.

ERG transcriptional networks in primary acute leukemia cells implicate a role for ERG in deregulated kinase signaling.

Bock J, Mochmann LH, Schlee C, Farhadi-Sartangi N, Göllner S, Müller-Tidow C, Baldus CD.

PLoS One. 2013;8(1):e52872. doi: 10.1371/journal.pone.0052872. Epub 2013 Jan 3.

42.

Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations.

Neumann M, Heesch S, Gökbuget N, Schwartz S, Schlee C, Benlasfer O, Farhadi-Sartangi N, Thibaut J, Burmeister T, Hoelzer D, Hofmann WK, Thiel E, Baldus CD.

Blood Cancer J. 2012 Jan;2(1):e55. doi: 10.1038/bcj.2011.49. Epub 2012 Jan 27.

43.

Antileukemic activity of the HSP70 inhibitor pifithrin-μ in acute leukemia.

Kaiser M, Kühnl A, Reins J, Fischer S, Ortiz-Tanchez J, Schlee C, Mochmann LH, Heesch S, Benlasfer O, Hofmann WK, Thiel E, Baldus CD.

Blood Cancer J. 2011 Jul;1(7):e28. doi: 10.1038/bcj.2011.28. Epub 2011 Jul 15.

44.

Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia.

Kühnl A, Gökbuget N, Kaiser M, Schlee C, Stroux A, Burmeister T, Mochmann LH, Hoelzer D, Hofmann WK, Thiel E, Baldus CD.

Blood. 2011 Dec 8;118(24):6362-7. doi: 10.1182/blood-2011-04-350850. Epub 2011 Oct 18.

45.

Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts.

Blau O, Baldus CD, Hofmann WK, Thiel G, Nolte F, Burmeister T, Türkmen S, Benlasfer O, Schümann E, Sindram A, Molkentin M, Mundlos S, Keilholz U, Thiel E, Blau IW.

Blood. 2011 Nov 17;118(20):5583-92. doi: 10.1182/blood-2011-03-343467. Epub 2011 Sep 23.

46.

High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia.

Kühnl A, Kaiser M, Neumann M, Fransecky L, Heesch S, Radmacher M, Marcucci G, Bloomfield CD, Hofmann WK, Thiel E, Baldus CD.

Leuk Res. 2011 Dec;35(12):1585-90. doi: 10.1016/j.leukres.2011.08.006. Epub 2011 Sep 6.

47.

Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG.

Mochmann LH, Bock J, Ortiz-Tánchez J, Schlee C, Bohne A, Neumann K, Hofmann WK, Thiel E, Baldus CD.

Oncogene. 2011 Apr 28;30(17):2044-56. doi: 10.1038/onc.2010.582. Epub 2011 Jan 17.

PMID:
21242973
48.

Epigenetic regulation of PAX5 expression in acute T-cell lymphoblastic leukemia.

Hütter G, Kaiser M, Neumann M, Mossner M, Nowak D, Baldus CD, Gökbuget N, Hoelzer D, Thiel E, Hofmann WK.

Leuk Res. 2011 May;35(5):614-9. doi: 10.1016/j.leukres.2010.11.015. Epub 2010 Dec 14.

PMID:
21156323
49.

Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Schwind S, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Whitman SP, Hickey C, Becker H, Metzeler KH, Paschka P, Baldus CD, Liu S, Garzon R, Powell BL, Kolitz JE, Carroll AJ, Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD.

J Clin Oncol. 2010 Dec 20;28(36):5257-64. doi: 10.1200/JCO.2010.29.2953. Epub 2010 Nov 15.

50.

Expression of IGFBP7 in acute leukemia is regulated by DNA methylation.

Heesch S, Bartram I, Neumann M, Reins J, Mossner M, Schlee C, Stroux A, Haferlach T, Goekbuget N, Hoelzer D, Hofmann WK, Thiel E, Baldus CD.

Cancer Sci. 2011 Jan;102(1):253-9. doi: 10.1111/j.1349-7006.2010.01760.x. Epub 2010 Oct 29.

Supplemental Content

Loading ...
Support Center